Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology

Panagiotis Kanellopoulos; Adam Mattsson; Ayman Abouzayed; Karim Obeid; Berthold A Nock; Vladimir Tolmachev; Theodosia Maina; Anna Orlova

doi:10.1186/s41181-024-00242-6

Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology

EJNMMI Radiopharm Chem. 2024 Feb 16;9(1):13. doi: 10.1186/s41181-024-00242-6.

Authors

Affiliations

¹ Department of Medicinal Chemistry, Uppsala University, 75183, Uppsala, Sweden.
² Molecular Radiopharmacy, INRaSTES, NCSR "Demokritos", 15341, Athens, Greece.
³ Department of Immunology, Genetics and Pathology, Uppsala University, 75183, Uppsala, Sweden.
⁴ Department of Medicinal Chemistry, Uppsala University, 75183, Uppsala, Sweden. anna.orlova@ilk.uu.se.
⁵ Science for Life Laboratory, Uppsala University, 75237, Uppsala, Sweden. anna.orlova@ilk.uu.se.

^# Contributed equally.

Abstract

Background: The gastrin-releasing peptide receptor (GRPR) has been extensively studied as a biomolecular target for peptide-based radiotheranostics. However, the lack of metabolic stability and the rapid clearance of peptide radioligands, including radiolabeled GRPR-antagonists, often impede clinical application. Aiming at circumventing these drawbacks, we have designed three new GRPR-antagonist radioligands using [^99mTc]Tc-DB15 ([^99mTc]Tc-N₄-AMA-DIG-_DPhe-Gln-Trp-Ala-Val-Sar-His-Leu-NHEt; AMA: p-aminomethylaniline; DIG: diglycolate) as a motif, due to its high GRPR-affinity and stability to neprilysin (NEP). The new analogues carry the DOTAGA-chelator (1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid) through different linkers at the N-terminus to allow for labeling with the theranostic radionuclide pair In-111/Lu-177. After labeling with In-111 the following radioligands were evaluated: (i) [¹¹¹In]In-AU-SAR-M1 ([¹¹¹In]In-DOTAGA-AMA-DIG-_DPhe-Gln-Trp-Ala-Val-Sar-His-Leu-NHEt), (ii) [¹¹¹In]In-AU-SAR-M2 ([¹¹¹In]In-[DOTAGA-Arg]AU-SAR-M1) and (iii) [¹¹¹In]In-AU-SAR-M3 ([¹¹¹In]In-[DOTAGA-_DArg]AU-SAR-M1).

Results: These radioligands were compared in a series of in vitro assays using prostate adenocarcinoma PC-3 cells and in murine models. They all displayed high and GRPR-specific uptake in PC-3 cells. Analysis of mice blood collected 5 min post-injection (pi) revealed similar or even higher metabolic stability of the new radioligands compared with [^99mTc]Tc-DB15. The stability could be further increased when the mice were treated with Entresto® to in situ induce NEP-inhibition. In PC-3 xenograft-bearing mice, [¹¹¹In]In-AU-SAR-M1 displayed the most favourable biodistribution profile, combining a good tumor retention with the highest tumor-to-organ ratios, with the kidneys as the dose-limiting organ.

Conclusions: These findings strongly point at AU-SAR-M1 as a promising radiotherapeutic candidate when labeled with Lu-177, or other medically appealing therapeutic radiometals, especially when combined with in situ NEP-inhibition. To this goal further investigations are currently pursued.

Keywords: GRPR-antagonist; Metabolic stability; NEP-inhibition; PC-3 tumors; Prostate cancer; Radiotheranostics.

Abstract

Grants and funding